© Reuters. FDA accepts Astellas' marketing application Myrbetriq/VESIcare combo for OAB
- The FDA accepts for review Astellas Pharma's (OTCPK:ALPMF)(OTCPK:) marketing application seeking approval for the combination of mirabegron and solifenacin for the treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. The agency's action date is April 28, 2018.
- In the U.S., each medication is approved as monotherapy to treat OAB, mirabegron as Myrbetriq and solifenacin as VESIcare.
- Now read: 3 Things In Biotech You Should Learn Today: August 24, 2017